Research progress on the characteristics, mechanism and intervention of cognitive impairment in schizophrenia

doi:10.3877/cma.j.issn.2095-655X.2023.01.006

Abstract

Abstract:

Schizophrenia is a serious mental illness with high incidence and high disability rate. As one of the core symptoms, cognitive impairment usually appears before psychotic symptoms, and most of them are difficult to alleviate. It has been found that the cognitive impairment of schizophrenia is widespread, which is easily influenced by genetic risk, abnormal self-experience and other factors. These factors frequently often cause a loss in social function and have an impact on the prognosis. At present, its pathophysiological mechanism is yet understood fully, although most studies agree that stress, a disordered balance of proinflammatory and anti-inflammatory cytokines, and the brain functional network are all relevant factors. Antipsychotics, cognitive therapy, and other techniques can help schizophrenia patients with their cognitive function. This study summarizes the studies on cognitive impairment in schizophrenia in order to better understand the process of cognitive impairment in schizophrenia and to provide fresh concepts for future research, diagnosis, and treatment.

Key words: Schizophrenia, Cognitive impairment, Mechanism, Intervention

Zhenzhen Yao, Angang Chen, Yanan Zhou, Gaofeng Zhao, Shenshuai Zhang, Jinguo Zhai, Min Chen. Research progress on the characteristics, mechanism and intervention of cognitive impairment in schizophrenia[J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(01): 28-32.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2023.01.006

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2023/V11/I01/28

References 50

[1]	Sheffield JM, Karcher NR, Barch DM.Cognitive deficits in psychotic disorders：a lifespan perspective[J].Neuropsychol Rev，2018，28(4):509-533.DOI：10.1007/s11065-018-9388-2.
[2]	Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery，part 1：test selection，reliability，and validity[J].Am J Psychiatry，2008，165(2):203-213.DOI：10.1176/appi.ajp.2007.07010042.
[3]	Mihaljević-Peleš A, Bajs Janović M, Šagud M, et al. Cognitive deficit in schizophrenia：an overview[J].Psychiatr Danub，2019，31(Suppl 2):139-142.
[4]	Zanelli J, Reichenberg A, Sandin S，et al.Dynamic and static cognitive deficits in schizophrenia and bipolar disorder after the first episode[J].Schizophr Bull，2022，48(3):590-598.DOI：10.1093/schbul/sbab150.
[5]	Wang DM, Du YX, Zhu RR，et al.The relationship between cognitive impairment and superoxide dismutase activity in untreated first-episode patients with schizophrenia[J].World J Biol Psychiatry，2022，23(7):517-524.DOI：10.1080/15622975.2021.2013093.
[6]	Xie YJ, Xi YB, Cui LB，et al.Functional connectivity of cerebellar dentate nucleus and cognitive impairments in patients with drug-naive and first-episode schizophrenia[J].Psychiatry Res，2021(300):113937.DOI：10.1016/j.psychres.2021.113937.
[7]	Hintze B, Rowicka M, Barczak A．Are executive functions deficits in early-onset chronic schizophrenia more severe than in adult-onset chronic schizophrenia？[J].Clin Neuropsychiatry，2022，19(1):54-63.DOI：10.36131/cnfioritieditore20220108.
[8]	陈声云，刘雅茜，张桂灿，等．稳定期精神分裂症患者神经认知功能损害特征及影响因素分析[J].国际精神病学杂志，2020，47(5):904-909.DOI：10.13479/j.cnki.jip.2020.05.015.
[9]	Van Haren N, Van Dam DS, Stellato RK.Change in IQ in schizophrenia patients and their siblings：a controlled longitudinal study[J].Psychol Med，2019，49(15):2573-2581.DOI：10.1017/S0033291718003537.
[10]	Zanelli J, Mollon J, Sandin S，et al.Cognitive change in schizophrenia and other psychoses in the decade following the first episode[J].Am J Psychiatry，2019，176(10):811-819.DOI：10.1176/appi.ajp.2019.18091088.
[11]	Fett AJ, Velthorst E, Reichenberg A，et al.Long-term changes in cognitive functioning in individuals with psychotic disorders：findings from the suffolk county mental health project[J].JAMA Psychiatry，2020，77(4):387-396.DOI：10.1001/jamapsychiatry.2019.3993.
[12]	Sosin D, Ivashchenko D, Sozaeva Z，et al.Cognitive impairment in patients with treatment resistant schizophrenia：associations with DRD2，DRD3，HTR2A，BDNF and CYP2D6 genetic polymorphisms[J].Neurology，Psychiatry and Brain Research，2019，33(6):48-55.DOI：10.1016/j.npbr.2019.06.003.
[13]	Hubbard L, Tansey KE, Rai D，et al.Evidence of common genetic overlap between schizophrenia and cognition[J].Schizophr Bull，2016，42(3):832-842.DOI：10.1093/schbul/sbv168.
[14]	Koch E, Nyberg L, Lundquist A，et al.Sex-specific effects of polygenic risk for schizophrenia on lifespan cognitive functioning in healthy individuals[J].Transl Psychiatry，2021，11(1):520.DOI：10.1038/s41398-021-01649-4.
[15]	Perkins DO, Olde Loohuis L, Barbee J，et al.Polygenic risk score contribution to psychosis prediction in a target population of persons at clinical high risk[J].Am J Psychiatry，2020，177(2):155-163.DOI：10.1176/appi.ajp.2019.18060721.
[16]	Shafee R, Nanda P, Padmanabhan JL，et al.Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls[J].Transl Psychiatry，2018，8(1):78.DOI：10.1038/s41398-018-0124-8.
[17]	He Q, Jantac Mam-Lam-Fook C, Chaignaud J，et al.Influence of polygenic risk scores for schizophrenia and resilience on the cognition of individuals at-risk for psychosis[J].Transl Psychiatry，2021，11(1):518.DOI：10.1038/s41398-021-01624-z.
[18]	Germine L, Robinson EB, Smoller JW，et al.Association between polygenic risk for schizophrenia，neurocognition and social cognition across development[J].Transl Psychiatry，2016，6(10):e924.DOI：10.1038/tp.2016.147.
[19]	Su X, Qiao L, Liu Q, et al. Genetic polymorphisms of BDNF on cognitive functions in drug-naive first episode patients with schizophrenia[J].Sci Rep，2021，11(1):20057.DOI：10.1038/s41598-021-99510-7.
[20]	Poddar I, Callahan PM, Hernandez CM，et al.Chronic oral treatment with risperidone impairs recognition memory and alters brain-derived neurotrophic factor and related signaling molecules in rats[J].Pharmacol Biochem Behav，2020(189):172853.DOI：10.1016/j.pbb.2020.172853.
[21]	Park S, Nasrallah HA.The varieties of anomalous self experiences in schizophrenia：splitting of the mind at a crossroad[J].Schizophr Res，2014，152(1):1-4.DOI：10.1016/j.schres.2013.11.036.
[22]	Trask CL, Matsui MM, Cohn JR，et al.Anomalous self-experiences in cognition are negatively associated with neurocognitive functioning in schizophrenia[J].Cogn Neuropsychiatry，2021，26(5):307-320.DOI：10.1080/13546805.2021.1935225.
[23]	Hernández-García M, Gómez-García M, Sotelo E，et al.Anomalous self-experiences are related to general cognition deficits in schizophrenia[J].Eur Arch Psychiatry Clin Neurosci，2021，271(4):707-712.DOI：10.1007/s00406-020-01213-z.
[24]	Kaneko K．Negative symptoms and cognitive impairments in schizophrenia：two key symptoms negatively influencing social functioning[J].Yonago Acta Med，2018，61(2):91-102.DOI：10.33160/yam.2018.06.001.
[25]	Tominaga T, Tomotake M, Takeda T，et al.Relationship between social and cognitive functions in people with schizophrenia[J].Neuropsychiatr Dis Treat，2018(14):2215-2224.DOI：10.2147/NDT.S171207.
[26]	Yeo BT, Krienen FM, Sepulcre J，et al.The organization of the human cerebral cortex estimated by intrinsic functional connectivity[J].J Neurophysiol，2011，106(3):1125-1165.DOI：10.1152/jn.00338.2011.
[27]	Gordon EM, Laumann TO, Marek S，et al.Default-mode network streams for coupling to language and control systems[J].Proc Natl Acad Sci USA，2020，117(29):17308-17319.DOI：10.1073/pnas.2005238117.
[28]	Smallwood J, Bernhardt BC, Leech R，et al.The default mode network in cognition：a topographical perspective[J].Nat Rev Neurosci，2021，22(8):503-513.DOI：10.1038/s41583-021-00474-4.
[29]	Khalil M, Hollander P, Raucher-Chéné D，et al.Structural brain correlates of cognitive function in schizophrenia：a meta-analysis[J].Neurosci Biobehav Rev，2022(132):37-49.DOI：10.1016/j.neubiorev.2021.11.034.
[30]	Chumakov E, Dorofeikova M, Tsyrenova K，et al.A cross-sectional study on associations between BDNF，CRP，IL-6 and clinical symptoms，cognitive and personal performance in patients with paranoid schizophrenia[J].Front Psychiatry，2022(13):943869.DOI：10.3389/fpsyt.2022.943869.
[31]	Baek SH, Kim H, Kim JW，et al.Association between peripheral inflammatory cytokines and cognitive function in patients with first-episode schizophrenia[J].J Pers Med，2022，12(7).DOI：10.3390/jpm12071137.
[32]	Kogan S, Ospina LH, Kimhy D．Inflammation in individuals with schizophrenia-implications for neurocognition and daily function[J].Brain Behav Immun，2018(74):296-299.DOI：10.1016/j.bbi.2018.09.016.
[33]	Xiu MH, Yang GG, Tan YL，et al.Decreased interleukin-10 serum levels in first-episode drug-naïve schizophrenia：relationship to psychopathology[J].Schizophr Res，2014，156(1):9-14.DOI：10.1016/j.schres.2014.03.024.
[34]	Thibaut F. Neuroinflammation: new vistas for neuropsychiatric research[J].Dialogues Clin Neurosci，2017，19(1):3-4.DOI：10.31887/DCNS.2017.19.1/fthibaut.
[35]	Rokita KI, Dauvermann MR, Mothersill D，et al.Current psychosocial stress，childhood trauma and cognition in patients with schizophrenia and healthy participants[J].Schizophr Res，2021(237):115-121.DOI：10.1016/j.schres.2021.08.030.
[36]	孔令明，朱晓丽，牛威，等．精神分裂症患者外周血lncRNA、童年期慢性应激与认知功能障碍的关系[J].中华行为医学与脑科学杂志，2021，30(11):1005-1010.DOI：10.3760/cma.j.cn371468-20210619-00334.
[37]	Piotrowski P, Kotowicz K, Rymaszewska J，et al.Allostatic load index and its clinical correlates at various stages of psychosis[J].Schizophr Res，2019(210):73-80.DOI：10.1016/j.schres.2019.06.009.
[38]	Zhou Y, Huang J, Zhang P，et al.Allostatic load effects on cortical and cognitive deficits in essentially normotensive，normoweight patients with schizophrenia[J].Schizophr Bull，2021，47(4):1048-1057.DOI：10.1093/schbul/sbaa196.
[39]	Azimi Sanavi M, Ghazvini H, Zargari M，et al.Effects of clozapine and risperidone antipsychotic drugs on the expression of CACNA1C and behavioral changes in rat 'Ketamine model of schizophrenia[J].Neurosci Lett，2022(770):136354.DOI：10.1016/j.neulet.2021.136354.
[40]	Rogóz Z, Kamińska K, Lech MA，et al.N-acetylcysteine and aripiprazole improve social behavior and cognition and modulate brain BDNF levels in a rat model of schizophrenia[J].Int J Mol Sci，2022，23(4).DOI：10.3390/ijms23042125.
[41]	Wu Z, Liu Q, Zhang Y，et al.Superoxide dismutase，BDNF，and cognitive improvement in drug-naive first-episode patients with schizophrenia：a 12-week longitudinal study[J].Int J Neuropsychopharmacol，2022，25(2):128-135.DOI：10.1093/ijnp/pyab065.
[42]	Setién-Suero E, Ortiz-García de la Foz V, Suárez-Pinilla P，et al.Different neurocognitive profiles of risperidone and aripiprazole in the FIRST episode of psychosis：a 3-year follow-up comparison[J].Prog Neuropsychopharmacol Biol Psychiatry，2021(110):110309.DOI：10.1016/j.pnpbp.2021.110309.
[43]	Joshi YB, Thomas ML, Braff DL，et al.Anticholinergic medication burden-associated cognitive impairment in schizophrenia[J].Am J Psychiatry，2021，178(9):838-847.DOI：10.1176/appi.ajp.2020.20081212.
[44]	Lindenmayer JP, Insel BJ, Khan A，et al.Effects of clozapine on neurocognitive functions in schizophrenia：a naturalistic comparison to non-clozapine antipsychotics[J].Innov Clin Neurosci，2021，18(10-12):40-46.
[45]	Singh A, Kumar V, Pathak H，et al.Effect of antipsychotic dose reduction on cognitive function in schizophrenia[J].Psychiatry Res，2022(308):114383.DOI：10.1016/j.psychres.2021.114383.
[46]	Zhu X, Fan H, Zou Y，et al.Computerized or manual? Long term effects of cognitive remediation on schizophrenia[J].Schizophr Res，2022(239):47-54.DOI：10.1016/j.schres.2021.11.019.
[47]	Katsumi A, Hoshino H, Fujimoto S, et al. Effects of cognitive remediation on cognitive and social functions in individuals with schizophrenia[J].Neuropsychol Rehabil，2019，29(9):1475-1487.DOI：10.1080/09602011.2017.1409639.
[48]	Buonocore M, Spangaro M, Bechi M，et al.Cognitive remediation in schizophrenia：what happens after 10 years？[J].Schizophr Res Cogn，2022(29):100251.DOI：10.1016/j.scog.2022.100251.
[49]	Khonsari NM, Badrfam R, Mohammdi MR，et al.Effect of aerobic exercise as adjunct therapy on the improvement of negative symptoms and cognitive impairment in patients with schizophrenia：a randomized，case-control clinical trial[J].J Psychosoc Nurs Ment Health Serv，2022，60(5):38-43.DOI：10.3928/02793695-20211014-03.
[50]	Wen N, Chen L, Miao X，et al.Effects of high-frequency rTMS on negative symptoms and cognitive function in hospitalized patients with chronic schizophrenia：a double-blind，sham-controlled pilot trial[J].Front Psychiatry，2021(12):736094.DOI：10.3389/fpsyt.2021.736094.

Please choose a citation manager

Content to export